NSCLC patients with high expression of HDAC and EZH2 have a low survival rate (Shi et al., 2019), and EGFR and PI3K are classic regulatory pathways involved in the development of LUAD (Wei et al., 2019; Shaurova et al., 2020). This evidence concerns the gene EZH2 and non-small cell lung carcinoma.